Bibliography
- Blumenfeld AM, Varon SF, Wilcox TK, Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15
- Bloudek LM, Stokes M, Buse DC, Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012;13:61-78
- Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6
- Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol 2009;22:269-76
- Diener HC, Dodick DW, Goadsby PJ, Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol 2012;8:162-71
- Lionetto L, Negro A, Palmisani S, Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17:393-406
- Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
- Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831-45
- Rapoport AM. The therapeutic future in headache. Neurol Sci 2012;33(Suppl 1):S119-25
- Färkkilä M, Diener HC, Géraud G, COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13
- Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012;13:271-5
- Dodick DW, Turkel CC, DeGryse RE, PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36
- Palma JA, Irimia P, Fernandez-Torron R, Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine. Rev Neurol 2012;54:705-11
- Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 2012;307:1736-45
- Lipton RB, Varon SF, Grosberg B, OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465-72